Table 5.
SNP | Chr. | Nearby genes of interest | Clinical stage ≥T3 or evidence of metastasis at time of diagnosis (Definition 1; n = 239) | WHO 3 or Gleason score ≥8 at time of diagnosis (Definition 2; n = 167) | Clinical stage ≥T3, evidence of metastasis, WHO 3, or Gleason score ≥8 at time of diagnosis (Definition 3; n = 319) | |||
---|---|---|---|---|---|---|---|---|
OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | |||
rs10486567 | 7 | JAZF1 | 0.80 (0.61–1.04) | 0.091 | 0.66 (0.47–0.92) | 0.013 | 0.75 (0.59–0.96) | 0.021 |
rs1016343 | 8 | MYC | 1.30 (1.02–1.66) | 0.035 | 1.34 (1.01–1.79) | 0.043 | 1.28 (1.03–1.58) | 0.024 |
rs10763588 | 10 | MSMB; NCOA4 | 1.28 (1.04–1.59) | 0.020 | 1.25 (0.97–1.62) | 0.081 | 1.18 (0.98–1.42) | 0.077 |
rs7098889 | 10 | MSMB; NCOA4 | 1.29 (1.04–1.59) | 0.018 | 1.22 (0.95–1.57) | 0.12 | 1.17 (0.97–1.41) | 0.092 |
rs10993994 | 10 | MSMB; NCOA4 | 1.30 (1.05–1.62) | 0.015 | 1.27 (0.98–1.64) | 0.072 | 1.19 (0.99–1.44) | 0.065 |
rs11228565 | 11 | TPCN2; MYEOV | 1.46 (1.14–1.88) | 0.0029 | 1.29 (0.95–1.75) | 0.096 | 1.38 (1.10–1.74) | 0.0049 |
rs11649743 | 17 | HNF1B | 0.76 (0.59–1.00) | 0.044 | 0.73 (0.52–1.01) | 0.061 | 0.76 (0.60–0.96) | 0.022 |
rs17632542 | 19 | KLK3 | 0.57 (0.35–0.92) | 0.021 | 1.07 (0.65–1.75) | 0.8 | 0.74 (0.50–1.10) | 0.13 |
SNP = single nucleotide polymorphism; Chr. = chromosome; WHO = World Health Organization; OR (95% CI): odds ratio and 95% confidence interval; p = p value for association test.